Plexium
  • Home
  • Platform
  • Pipeline
  • Team
  • Careers
  • News
  • Contact
Select Page

Plexium Appoints Stephen Mullennix as Chief Financial Officer

by Plexium | May 3, 2022 | Press Releases

San Diego, California, [May 3, 2022] – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Stephen Mullennix as Chief Financial Officer (CFO). Mr. Mullennix brings more than 20 years of...

Abbvie and Plexium Enter into Multi-target Strategic Collaboration to Develop and Commercialize Targeted Protein Degradation Therapies for Neurological Conditions

by Plexium | Apr 28, 2022 | Press Releases

San Diego, California, [April 28, 2022] – Plexium, Inc. (Plexium) and AbbVie (NYSE: ABBV) have entered into an exclusive strategic collaboration to develop and commercialize novel Targeted Protein Degradation (TPD) therapeutics for neurological conditions. This...

Plexium Announces Participation of its CEO, Percival Barretto-Ko, at Longwood Healthcare Leaders Spring MIT Web Conference

by Plexium | Apr 6, 2022 | Press Releases

San Diego, California, April 6, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced that Plexium President & CEO, Percival Barretto-Ko, will participate at the Longwood Healthcare Leaders Spring MIT...

Plexium Announces $102m Financing to Advance Pipeline of Targeted Protein Degradation Therapies and Technology Platform

by Plexium | Feb 23, 2022 | Press Releases

San Diego, California, Feb. 23, 2022 – Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the completion of an oversubscribed $102M financing, led by BVF Partners, L.P. and TCG X, with participation from new...

Amgen and Plexium Announce Multi-year, Drug Discovery Collaboration to Identify Novel Targeted Protein Degradation Therapies

by Plexium | Feb 3, 2022 | Press Releases

Collaboration Combines Plexium’s Novel Technology Platform With Amgen’s Early Discovery Expertise to Identify and Develop new Therapeutic Agents in Cancer and Other Serious Diseases THOUSAND OAKS and San Diego, Calif. (Feb. 03, 2022) – Amgen (NASDAQ:AMGN) and Plexium,...
« Older Entries

Categories

  • All Posts
  • Events
  • Press Releases
  • ©2022 Plexium, Inc., All rights reserved
  • Privacy Policy
  • Terms of use
  • Twitter
  • LinkedIn
  • Facebook

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Do not sell my personal information.
Cookie settingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT